Pioneering next generation therapeutics to treat severe, chronic inflammation-driven diseases

Mission & Values

Our mission is to improve the lives of patients by developing groundbreaking therapeutics for inflammation-driven neurodegenerative diseases, autoimmune disorders and selected cancers..

Our talented and dedicated team of scientists and professionals is continuously pushing the boundaries of scientific innovation, guided by our unwavering commitment to patients. We uphold the highest standards of quality and ethics and strive for excellence in every aspect of our work. We embrace change and challenge conventional thinking. Our diverse team, encompassing a wealth of backgrounds and perspectives, fosters a collaborative environment where individuals can thrive and be their authentic selves.

Team

Montis Biosciences Team

Management Team

Gil Beyen

Gil Beyen

Chief Executive Officer and Executive Director

Read More
Mohammed (Mo) Benkheil

Mohammed (Mo) Benkheil

Director Biology

Read More

Supported by experienced advisors

Carol Walton

Carol Walton

BD Advisor
Argenx - GSK
Clare Jones

Clare Jones

Science Advisor
Talisman - MedImmune - Astra Zeneca
Ottavio Vitolo

Ottavio Vitolo

Medical Advisor
HMS - Massachusetts General Hospital - Cerevance - Pfizer
Iman El-Hariry
Medical Advisor
Erytech - Syntha - GSK
Beatriz Goyenechea

Beatriz Goyenechea

mAb Advisor
Starbio - Tusk - F-star

Investors

Our Science

Montis Biosciences is a preclinical-stage biopharmaceutical company advancing innovative therapeutics to treat inflammation-driven neurodegenerative diseases, autoimmune disorders and selected cancers. Leveraging its patient-centric discovery platform, Montis is advancing unique and potent antibodies to bring new treatment options to those patients.

Montis’ lead program, MB01, focuses on modulating the multifaceted roles of C1q, the activator of the classical complement pathway and a key immune system mediator in neuroinflammatory and autoimmune disorders. 

Unlike existing classical complement targeting approaches that focus on blocking the classical complement pathway, Montis has discovered novel anti-C1q antibodies, capable of modulating C1q’s complement-independent functions with or without inhibiting the classical complement cascade. These antibodies hold the potential to offer a paradigm shift in the complement field and to revolutionize treatments for certain neurodegenerative diseases and autoimmune neuropathies. Based on extensive in vitro end in vivo evaluation, Montis has selected potent the drug candidates and is working to advance them to IND enabling work and clinical evaluation in diseases of high unmet medical need.

Montis’ second program (MB02) focuses on inhibiting CD93, a novel perivascular target, in lung squamous cell carcinoma (LUSC). A potent drug candidate was selected, holding best-in-class potential in this inflammation-driven and underserved oncology indication. Montis plans to partner this promising asset.

Montis is backed by a strong investor syndicate, including Droia Ventures, Pfizer Ventures, Polaris Innovation Fund, ALSA Ventures and VIB, and is led by a team with extensive drug development experience.

Pipeline

Scientific founders & advisors

Peter Karmeliet
Scientific founder
  • Professor at Faculty of Medecine, KU Leuven
  • Distinguished expert on endothelial cell biology
Peter Carmeliet

Tom Eirik Mollness, MD, PhD

  • Professor at the University of Oslo, leading the Norwegian Complement Research Group
  • Specialized in the role of complement in human disease 
Max Mazzone
Scientific founder
  • Professor at Faculty of Medecine, KU Leuven
  • Expert of macrophages and tumor immunity
Thomas Sharp

Thomas Sharp, PhD

  • Associate Professor at University of Bristol
  • Specialized in visualising complement activation
Andrea Tenner

Andrea Tenner, PhD

  • Professor at University of California, Irvine
  • Specialized in the role of the complement system in neurodegenerative
Mohamed Daha

Mohamed Daha, PhD

  • Emeritus Professor of Immunology at UMC Leiden
  • Specialized in the role of complement in innate- and autoimmunity
Bart De Strooper

Bart De Strooper, MD, PhD

  • Professor of Medecine at KU Leuven and UK Dementia Research Institute
  • Distinguished expert in Alzheimer disease

Careers

Montis Biosciences is a young innovative biotech company based just outside Leuven, Belgium.

We are committed to developing cutting-edge therapies for the treatment of serious diseases and we want to make a positive impact on the lives of patients around the world.

Montis Biosciences creates a collaborative and supportive environment where employees are empowered to reach their full potential. We value teamwork, innovation and creativity and we are committed to fostering a culture of respect, diversity, inclusion and open communication.

Current career opportunities

There are no open positions for the moment, but feel free to send your spontaneous application to info@montisbio.com.

Contact 

Montis Biosciences

Arenberg Bio-Accelerator
Gaston Geenslaan 3
3001 Leuven
Belgium

info@montisbio.com